$MSLP FORM 4 < > Check this box if no longer

goarmy123 · 2012-05-14T20:17:21-04:00

$MSLP FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 1. Name and Address of Reporting Person * DELUCA JEREMY R. 2. Issuer Name and Ticker or Trading Symbol MusclePharm Corp 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director __ X __ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) Co-Pres. Chief Mktg. Ofc. (Last) (First) (Middle) 4721 IRONTON STREET,, BUILDING A 3. Date of Earliest Transaction (MM/DD/YYYY) 4/25/2012 (Street) DENVER, CO 80239 (City) (State) (Zip) 4. If Amendment, Date Original Filed (MM/DD/YYYY) 6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 4/25/2012 P 500000 A $.019 148682972 D Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivate Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other DELUCA JEREMY R. 4721 IRONTON STREET, BUILDING A DENVER, CO 80239 X X Co-Pres. Chief Mktg. Ofc. Signatures /s/ Jeremy Deluca 4/30/2012 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4(b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

New Post Public Reply Private Reply Replies (0) Message Board

Newer Older

goarmy123

May 14, 2012 at 8:17 PM

$MSLP

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^* DELUCA JEREMY R.	2. Issuer Name and Ticker or Trading Symbol MusclePharm Corp [ MSLP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director __ X __ 10% Owner __ X __ Officer (give title below) _____ Other (specify below) Co-Pres. & Chief Mktg. Ofc.
(Last) (First) (Middle) 4721 IRONTON STREET,, BUILDING A	3. Date of Earliest Transaction (MM/DD/YYYY) 4/25/2012
(Street) DENVER, CO 80239 (City) (State) (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	4/25/2012		P		500000	A	$.019	148682972	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)			11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
DELUCA JEREMY R. 4721 IRONTON STREET, BUILDING A DENVER, CO 80239	X	X	Co-Pres. & Chief Mktg. Ofc.

Signatures
/s/ Jeremy Deluca		4/30/2012
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

MusclePharm Corporation. (MSLPQ) Stock Research Links

MSLPQ Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Novartis Pulls the Plug on BioArctic Agreement

Novartis Drops BioArctic Like a Hot Potato Well, folks, it looks like Novartis has decided to pack up its bags and hightail it out of its collaboration with BioArctic AB. This ain't just any small piece of news—it's got ramifications that have folks in the biotech and healthcare sector scratching their heads and, probably, feeling a mixture of apprehension and...

NABEP Powers Ahead with Orinoco Furnace Restart

Revving Up the Engines in the Orinoco Belt And HERE we are again, ringing the bell on another bold move in the world of energy. NABEP is pulling back the curtain on their revamped activities in the Orinoco Belt. You're telling me they just fired up one heck of a furnace? In this relentless pursuit to spike their output, you've gotta respect the hustle. It's like cranking...

Differentia Bio's AI: Transforming Drug Development Dynamics

The Future of Drug Development: AI's New Role When it comes to pharmaceutical R&D, Some outfits are playing pin the tail on the donkey, but Differentia Bio over here is sharpening the pin with some futuristic gadgetry. Yep, they're jazzing up the game with AI-powered digital twins, building lifelike disease environments that predict therapeutic outcomes with precision...

Business Formations in 2026: A Blow-by-Blow Analysis

Surging Entrepreneurial Spirit in 2026 Just when you’d think economic jitters would slow us down, American entrepreneurship is out there smashing records like a bulldozer through a picket fence. September 2026 saw a staggering 562,579 new business formations—the highest September tally ever logged. That's no fluke. This momentum hasn’t let up all year, and it paints...

TEKLYNX 2026: Revolutionizing Barcode Labeling Tech

In the ever-evolving world of supply chain technology, a big move by TEKLYNX is making waves. The 2026 version of their barcode labeling software isn't just an upgrade—it's a full-blown transformation. They've fine-tuned their suite to align with the latest industry standards and integrated fresh capabilities that scream future-proofing. TEKLYNX's Game-Changing Upgrades...

Hunan Courts European Investors with Strategic Initiatives

Seizing the European Spotlight You've heard of places making a splash, but Hunan smashing through the scene in Europe? Now that's a move you don't see every day. This Chinese province is dead set on stealing the European investment show, with a slick meet-and-greet tour across Germany and Switzerland. What's cooking in Hunan isn't your typical rice porridge—it's a...

Waters Acquires MOBILion: Ion Mobility Meets AI

MOBILion Joins Waters' Fold: A New Era for Proteomics Ah, the biotech world just saw another big whirl with Waters Corporation snagging MOBILion Systems. Now, this isn't just some stroll in the market park. We're talking about weaving MOBILion's fancy high-resolution ion mobility separation tech right into Waters' already robust mass spectrometry setup. These folks are...

KOVE's Bold Lineup Expansion at EICMA 2026

What's Roaring: The Latest from KOVE Anybody who’s been following motorcycle trends knows that EICMA 2026 was destined to be a spectacle, and KOVE didn’t disappoint. They rolled out a fleet of five new models, including the 125 RALLY, 350 RALLY, 650RR, and two head-turners on the electric front: the BONIC and the E-500RR. Each model brings something fresh to the...

Qapture's Institutional Stablecoin Venture Unveiled

Stablecoin Strategy Meets Institutional Investment Here's a fresh one from the digital asset universe. We're talking about Qapture Investments' bold move to launch an institutional-grade stablecoin yield strategy. This ain't your average kitchen table crypto chat—it's the Qapture Safe Haven Vault (QHVN-USD), tailored for those looking to get a better return on their...

How Octopus AI Reinvents Financial Processes in 2026

Stepping into 2026, the buzz in enterprise finance isn’t about a new gadget or slick marketing trick; it's about complex financial processes being tamed by artificial intelligence. Octopus AI is trying to spearhead this transition by automating the intricacies of financial workflows while ensuring that human judgment remains at the helm. The Austin, Texas outfit laid...